Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:427826rdf:typepubmed:Citationlld:pubmed
pubmed-article:427826lifeskim:mentionsumls-concept:C1516213lld:lifeskim
pubmed-article:427826lifeskim:mentionsumls-concept:C0025605lld:lifeskim
pubmed-article:427826lifeskim:mentionsumls-concept:C0205464lld:lifeskim
pubmed-article:427826lifeskim:mentionsumls-concept:C0205210lld:lifeskim
pubmed-article:427826lifeskim:mentionsumls-concept:C1524063lld:lifeskim
pubmed-article:427826pubmed:issue3lld:pubmed
pubmed-article:427826pubmed:dateCreated1979-6-29lld:pubmed
pubmed-article:427826pubmed:abstractTextThe manufacturer's recommended dose of methadone, which is 2.5-10 mg every 3-4 hours, is excessive. Methadone has an average primary-phase half-life of 14.3 hours and a slower secondary-phase half-life averaging 54.8 hours. Administering the recommended dose of methadone and escalating doses within 2-3 days may lead to very high plasma levels of the drug. In addition, factors such as drug-drug interaction and/or hepatic and renal dysfunction may affect the metabolism of methadone and result in its accumulation. Methadone is an effective analgesic whose pharmacokinetics must be appreciated in order for it to be used safely and effectively. Three cases of methadone overdose are presented.lld:pubmed
pubmed-article:427826pubmed:languageenglld:pubmed
pubmed-article:427826pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:427826pubmed:citationSubsetIMlld:pubmed
pubmed-article:427826pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:427826pubmed:statusMEDLINElld:pubmed
pubmed-article:427826pubmed:monthMarlld:pubmed
pubmed-article:427826pubmed:issn0361-5960lld:pubmed
pubmed-article:427826pubmed:authorpubmed-author:EttingerD SDSlld:pubmed
pubmed-article:427826pubmed:authorpubmed-author:VitaleP JPJlld:pubmed
pubmed-article:427826pubmed:authorpubmed-author:TrumpD LDLlld:pubmed
pubmed-article:427826pubmed:issnTypePrintlld:pubmed
pubmed-article:427826pubmed:volume63lld:pubmed
pubmed-article:427826pubmed:ownerNLMlld:pubmed
pubmed-article:427826pubmed:authorsCompleteYlld:pubmed
pubmed-article:427826pubmed:pagination457-9lld:pubmed
pubmed-article:427826pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:427826pubmed:meshHeadingpubmed-meshheading:427826-H...lld:pubmed
pubmed-article:427826pubmed:meshHeadingpubmed-meshheading:427826-N...lld:pubmed
pubmed-article:427826pubmed:meshHeadingpubmed-meshheading:427826-A...lld:pubmed
pubmed-article:427826pubmed:meshHeadingpubmed-meshheading:427826-P...lld:pubmed
pubmed-article:427826pubmed:meshHeadingpubmed-meshheading:427826-F...lld:pubmed
pubmed-article:427826pubmed:meshHeadingpubmed-meshheading:427826-M...lld:pubmed
pubmed-article:427826pubmed:meshHeadingpubmed-meshheading:427826-M...lld:pubmed
pubmed-article:427826pubmed:meshHeadingpubmed-meshheading:427826-A...lld:pubmed
pubmed-article:427826pubmed:meshHeadingpubmed-meshheading:427826-M...lld:pubmed
pubmed-article:427826pubmed:meshHeadingpubmed-meshheading:427826-D...lld:pubmed
pubmed-article:427826pubmed:year1979lld:pubmed
pubmed-article:427826pubmed:articleTitleImportant clinical pharmacologic considerations in the use of methadone in cancer patients.lld:pubmed
pubmed-article:427826pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:427826pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
pubmed-article:427826pubmed:publicationTypeCase Reportslld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:427826lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:427826lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:427826lld:pubmed